Nov. 22 at 6:01 PM
$VKTX $LLY $PFE
Of course, a phase 2 study focuses on dosing levels in orser to determine what doses and potential titrations manximize efficacy and minimize AEs. That said, Viking will file an IND for their amylin formulary by EOY, putting them about two years behind Lilly's entrant.
It almost looks like Viking is Lilly's Mini Me, gicen their GLP-1/GIP dual agonist and amylin formularies. Viking is also working on a calcitonin agonist that, with amylin, will yield another dual agonist, DACRA, that may be another game-changer. Eventually, all four might be balanced in a quad-agonist offering, though that's pretty far in the future.
